8-Azaadenosine

• UNSPSC Description:

  8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells[1][2].

• Target Antigen:

  Adenosine Deaminase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/8-azaadenosine.html

• Purity:

  99.97

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)|H2O : 3.33 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  NC1=NC=NC2=C1N=NN2[C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO

• Molecular Weight:

  268.23

• References & Citations:

  [1]Maria Anna Zipeto, et al. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell. 2016 Aug 4;19(2):177-191.|[2]Julia Ramírez-Moya, et al. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. Oncogene. 2020 Apr;39(18):3738-3753.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  10299-44-2